Wellpoint

Preapprovals for Genetic Testing

For Total Choice, PLUS, and Community Choice members

Effective July 1, 2024

To contact Carelon Medical Benefits Management:

866-766-0247 (toll free)
www.providerportal.com

Genetic tests that need preapproval

- Analysis of KRAS Status
- Analysis of PIK3CA Status in Tumor Cells
- Analysis of RAS Status
- BCR-ABL Mutation Analysis
- BRAF Mutation Analysis
- BRCA Genetic Testing
- Cardiac Ion Channel Genetic Testing
- Cell-Free Fetal DNA-Based Prenatal Screening for Fetal Aneuploidy
- Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies
- Circulating Tumor DNA Panel Testing (Liquid Biopsy)
- Detection and Quantification of Tumor DNA Using Next Generation Sequencing in Lymphoid Cancers
- DMD (dystrophin) Deletion Analysis
- DNA-Based Testing for Adolescent Idiopathic Scoliosis
- Epidermal Growth Factor Receptor (EGFR) Testing
- Gene-Based Tests for Screening, Detection and Management of Prostate Cancer
- Gene Expression Profile Tests for Multiple Myeloma
- Gene Expression Profiling and Genomic Biomarker Tests for Prostate Cancer
- Gene Expression Profiling for Bladder Cancer
- Gene Expression Profiling for Cancers of Unknown Primary Site
- Gene Expression Profiling for Colorectal Cancer
- Gene Expression Profiling for Coronary Artery Disease
- Gene Expression Profiling for Managing Breast Cancer Treatment
- Gene Expression Profiling for Risk Stratification of Inflammatory Bowel Disease (IBD)
- Gene Expression Profiling of Melanomas and Cutaneous Squamous Cell Carcinoma
- Gene Mutation Testing for Cancer Susceptibility and Management
- Genetic Testing and Biochemical Markers for the Diagnosis of Alzheimer's Disease
- Genetic Testing for Breast and/or Ovarian Cancer Syndrome

(continued on other side)

- Genetic Testing for Cancer Susceptibility
- Genetic Testing for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Syndrome
- Genetic Testing for CHARGE Syndrome
- Genetic Testing for Colorectal Cancer Susceptibility
- Genetic Testing for Diagnosis and Management of Hereditary Cardiomyopathies (including ARVD/C)
- Genetic Testing for Endocrine Gland Cancer Susceptibility
- Genetic Testing for Frontotemporal Dementia (FTD)
- Genetic Testing for Hereditary Pancreatitis
- Genetic Testing for Heritable Cardiac Conditions
- Genetic Testing for Inherited Diseases
- Genetic Testing for Inherited Peripheral Neuropathies
- Genetic Testing for Lynch Syndrome
- Genetic Testing for Macular Degeneration
- Genetic Testing for PTEN Hamartoma Tumor Syndrome
- Genetic Testing for Statin-Induced Myopathy
- Genetic Testing for TP53 Mutations (Li-Fraumeni Syndrome)
- Genetic Testing of an Individual's Genome for Inherited Diseases
- Genetic Testing to Confirm the Identity of Laboratory Specimens
- Genetic Testing to Detect, Diagnose and Manage Cancer
- Genotype Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status
- In Vitro Companion Diagnostic Devices
- Janus Kinase 2 (JAK2) V617F Gene Mutation Assay
- Metagenomic Sequencing for Infectious Diseas
- Methylenetetrahydrofolate Reductase Mutation Testing
- Molecular Marker Evaluation of Thyroid Nodules
- Molecular Profiling for the Evaluation of Malignant Tumors
- Panel and other Multi-Gene Testing for Polymorphisms to Determine Drug-Metabolizer Status
- Panexia™ Test for Oncologic Indications
- PIK3CA Mutation Testing for Malignant Conditions
- Preconceptional or Prenatal Genetic Testing of a Parent or Prospective Parent
- Preimplantation Genetic Diagnosis Testing
- Proteogenomic Testing for the Evaluation of Malignancies
- Prothrombin G20210A (Factor II) Mutation Testing
- RET Proto-oncogene Testing for Endocrine Gland Cancer Susceptibility
- SensiGene® Fetal RhD Genotyping Test
- TruGraf Blood Gene Expression Test for Transplant Monitoring
- Whole Genome Sequencing, Exome Sequencing, Gene Panels, and Molecular Profiling